Does Novartis have a support program for patients?
Novartis Patient Support™ offers a dedicated team to help provide a range of support services for your patients—from insurance and financial to clinical testing and ongoing support. See below to learn more about available support for KISQALI® (ribociclib).
Novartis Patient Support is a comprehensive program that is designed to help your eligible patients start, stay, and save on KISQALI
We support your patient’s journey with:
Dedicated assistance with access and reimbursement
Personalized support for your patients on therapy
Single points of contact for you and your patients
Insurance Support
Help navigating the insurance process, including benefits verification and support with the prior authorization (PA) and appeals processes.
Benefits Verification
Once you’ve enrolled your patients in Novartis Patient Support, our team will conduct a benefits verification to help you better understand your patients’ coverage, including:
Working with your patients’ health plans to understand coverage for KISQALI
Informing your practice about additional requirements, such as prior authorization
Identifying savings options available to your patients
PAs and Appeals
Novartis Patient Support can help with PA requests or letters of appeal by providing information to you or your office, including:
Providing best practices and timely updates via phone
Sharing helpful resources about the PA and appeals process, including:
KISQALI Access & Coverage
For the majority of patients with prescription drug insurance coverage, all or nearly all of the cost of KISQALI is covered, and prior authorizations are approved within 1 day.
For Medicare members, nearly 90% of KISQALI out-of-pocket costs were between $0 and $20 per month1
For patients with commercial insurance, approximately 80% of KISQALI out-of-pocket costs were between $0 and $50 per month1
More than 9 out of 10 patients have preferred formulary coverage for KISQALI2,*
More than 90% of KISQALI PAs are approved in less than 24 hours3
Novartis does not guarantee payment or coverage for any product or service. Actual coverage and reimbursement decisions are made by individual payers following receipt of claims. Coverage is subject to change by the relevant payer.
*>98% unrestricted coverage in Commercial and Medicare, based on MMIT data, as of June 2026.
References: 1. Data on file. Kisqali IQVIA data through November 2025. Novartis Pharmaceuticals Corp; 2026. 2. Data on file. Kisqali MMIT data June 2026. Novartis Pharmaceuticals Corp; 2026. 3. Data on file. Kisqali CMM AMP data review February 2026. Novartis Pharmaceuticals Corp; 2026.
Financial Support
Assist with connecting patients to relevant savings options.
At Novartis Patient Support, we understand that affordability is important to treatment success. That’s why we offer a range of savings options to help your patients access treatment, regardless of their ability to pay.
Co-Pay Plus
We help make treatment more affordable for your eligible patients through our Co-Pay Plus offer.
To sign up for the $0 Co-Pay Plus offer:
Swipe to see all options →
Patients can sign up online
Patients can call Novartis Patient Support to enroll at 866-433-8000
Providers, with their patients, can complete our Start Form and send it to Novartis Patient Support
Fill out the electronic Start Form on the CoverMyMeds® portal by visiting CoverMyMeds.health
CoverMyMeds is a registered trademark of CoverMyMeds LLC.
Offer valid only when used with commercial health insurance. Offer is not available where:
- the patient has federal or state health plan benefits (e.g., Medicare, Medicaid, TRICARE, VA);
- the health plan reimburses for the entire cost of the drug;
- the health plan provides no coverage for the drug; or
- prohibited by law.
The Program is designed exclusively for the benefit of the patient. The amount of available funding may be reduced or eliminated if it is not credited by the patient’s health plan toward the patient’s out-of-pocket obligations (e.g., deductibles, annual out-of-pocket maximums). Program funding may also be reduced or eliminated if the patient’s health plan, directly or indirectly, adjusts, reduces, or waives the patient’s health plan benefits based on the availability of, or the patient’s enrollment in, the Program, or otherwise acts in a manner that materially affects these Terms and Conditions.
Only the patient or their legal guardian or caregiver may enroll the patient in the Program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives (individually and collectively “Plan Administrators”), are prohibited from enrolling patients in the Program.
Patients in the Program are responsible for notifying Novartis of any change in their prescription drug health plan coverage that may conflict or otherwise affect compliance with these Terms and Conditions. By accepting Program funding from Novartis on behalf of participating patients, Plan Administrators agree to not take any action that materially affects compliance with these Terms and Conditions.
Patients may not seek reimbursement for the value received from the Program from any other party (e.g., health plans, flexible spending or healthcare savings accounts). Patients are responsible for complying with any applicable limitations and requirements of their health plan related to their use of the Program.
Valid only in the United States and Puerto Rico. For purchasers of FEMARA only, this is NOT valid for Massachusetts patients and is only valid for California patients that meet additional eligibility criteria.
The Program is not health insurance, and may not be combined with any third-party rebate, coupon, or offer. Novartis reserves the right to rescind, revoke, or amend the Program at any time without notice.
The Bridge Program
Up to 5 free treatment cycles of KISQALI for eligible patients through the Bridge Program† while health plan coverage is pursued.
Once patients enroll in Novartis Patient Support, we automatically identify if they are eligible for the Bridge Program based on the results of the benefits verification.
Eligible patients can receive up to 5 free treatment cycles of KISQALI.
Privately insured patients waiting for their coverage to take effect for KISQALI and/or FEMARA® (including generic letrozole) may be eligible for an additional supply of KISQALI that could continue for up to 5 treatment cycles.
Once we’ve determined your patient’s coverage status, we’ll help transition them to any appropriate financial support offering.
To enroll your eligible patient in this patient support service, submit a completed Novartis Patient Support Start Form or reach out to your Dedicated Novartis Associate Director, Access & Reimbursement (ADAR).
The Novartis Patient Assistance Foundation, Inc (NPAF)
Novartis Patient Assistance Foundation, Inc. (NPAF), an independent 501(c)(3) non-profit organization, provides Novartis medications free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication.
To be eligible, patients must:
Reside in the United States or a US territory
Be treated by a licensed US health care provider on an outpatient basis
Meet income and insurance guidelines
Visit PAP.Novartis.com or call NPAF at 800-277-2254 to learn more about eligibility and how to apply.
Clinical Testing and Support
We provide workflow support and options for testing, including:
ECG device program so your patients can receive their ECG assessment in seconds in your office or at home
There is no direct cost to you or your patients for participating in this program.
Download the Start Form to fill out applicable information for ECG testing support.
Limitations apply. KISQALI ECG Device Monitoring Program is only permitted to be used for monitoring or evaluating a patient for the current or potential administration of ribociclib. The equipment or services are not permitted to be used for any purpose outside of the scope of the program. You must not bill any entity or person for any equipment or services relating to the provision or interpretation of the ECG. In the event that you fail to abide by the rules of the KISQALI ECG Device Monitoring Program, your participation in the program may be terminated or modified at any time without prior notice, and you may be subject to additional remedies. Additional terms and conditions apply.
Sunshine Act costs may apply.
ECG, electrocardiogram.
To learn more, contact your dedicated Novartis Patient Support Team at 866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
Ongoing Support
Novartis Patient Support provides patients with ongoing help to stay on track with their KISQALI treatment plan, including:
A dedicated Novartis Patient Support Team member to answer their questions at every step
Information on financial support options
Help navigating health care changes
Tips for setting up a routine that can help patients stay on track with their medication dosing
Educational resources about KISQALI and living with breast cancer
Tips for talking to their health care provider
Email communications tailored to their treatment journey
A choice of texts and calls, including tips to keep them on track
To learn more, contact your dedicated Novartis Patient Support Team at 866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.
Getting Patients Started With Novartis Patient Support
CoverMyMeds is a registered trademark of CoverMyMeds LLC.
Resources
Novartis Patient Support has helpful resources to support your patient’s treatment journey.
Start Form
Start Form Guide
ICD-10-CM Flashcard
KISQALI Access Support Guide
Formulary Change Flashcard
KISQALI ECG Program Brochure
KISQALI Financial Assistance Brochure
Co-Pay Plus Enrollment Guide
Questions?
For more information on available resources, call Novartis Patient Support at 866-433-8000, Monday-Friday, 8:00 AM - 8:00 PM ET, excluding holidays.